

Table 2. Design and descriptive summary of studies in the Proof-ATHERO consortium

Study acronym or first author	Country	Population source	Population type	Years of baseline	No.	♀, %	Mean age, years (SD)
General population							
AIR	Sweden	Population register	General population	1995-97	391	0	58 (0.1)
ARIC	USA	Household listings	General population	1986-90	15,121	55	54 (6)
BRUN	Italy	Population register	General population	1990	933	49	59 (11)
CAPS	Germany	Electoral rolls	General population	1995-00	6,970	51	51 (13)
CCCC	Taiwan	Community screening	General population	1990-91	3,602	53	55 (12)
CHS	USA	Medicare lists	General population	1989-93	5,888	57	73 (6)
CMCS-BEIJING	China	Population register	General population	2002	1,324	53	60 (8)
DIWA	Sweden	Population register	General population	2001-04	644	100	64 (0.3)
EAS	Scotland	GP lists	General population	1987-88	1,115	50	64 (6)
EPICARDIAN	Spain	Population register	General population	1993-04	446	59	68 (12)
EVA	France	Electoral rolls	General population	1992-93	1,135	59	65 (3)
HOORN	Netherlands	Population register	General population	1999-01	780	50	69 (7)
INVADE	Germany	Insurance company	General population	2001-03	3,908	59	68 (8)
JHS	USA	Household listings	General population	2000-04	3,883	63	55 (13)
KIHD	Finland	Population register	General population	1987-89	1,399	0	52 (6)
MESA	USA	Household listings	General population	2000-02	6,814	53	62 (10)
NOMAS-INVEST	USA	Random digit dialing	General population	1993-01	856	62	66 (8)
PIVUS	Sweden	Population register	General population	2001-04	1,016	50	70 (0.0)
PLIC	Italy	Hospital	General population	1998-03	1,782	59	55 (11)
ROTTERDAM	Netherlands	Population register	General population	1990-93	7,983	61	71 (10)
SAPHIR	Austria	GP lists/advert	General population	1999-02	1,794	37	52 (6)
High-risk populations							
BK REGISTRY	Korea	Hospital	CHD	2000-07	1,000	44	60 (10)
CREED	Italy	Hospital	On haemodialysis/CAPD	1997-98	138	41	60 (16)
CSN	Italy	GP lists	Hypertension	1980-14	14,158	44	53 (13)
Ekar	Slovenia	Hospital	On haemodialysis	1996-05	54	50	55 (15)
HD-IMT	Serbia	Hospital	On haemodialysis	2004-05	85	39	59 (12)
Honda	Japan	Hospital	On haemodialysis	2005-07	313	39	61 (13)
IMPROVE	Multinational	Hospital/community screening	≥3 CVD RFs	2004-05	3,703	52	64 (5)
Kato	Japan	Hospital	On haemodialysis	2008-09	284	30	64 (12)
Landecho	Spain	Hospital	Early kidney disease	1999-11	250	12	55 (10)
NIGUARDA-MONZINO	Italy	Hospital	Lipid clinic patients/ CVD RFs	1984-10	1,564	41	56 (12)
OSACA2	Japan	Hospital	≥1 atherosclerotic RF	2000-03	291	40	65 (9)
Papagianni	Greece	Hospital	On haemodialysis	2001	83	46	58 (15)
POPROSTU	Poland	Hospital	T1DM	1999	96	33	24 (6)
RIAS	Switzerland	Hospital	≥1 CVD RF/CVD	1999-00	145	43	64 (13)
SPARC	Canada	Hospital	Carotid plaque	2006-08	349	43	71 (9)
3SCO	Japan	Hospital	≥1 CVD RF	2007	164	74	80 (6)
Clinical trials							
ACAPS	USA	Mailing lists/ community screening	LDL-C 130-189 mg/dL	1989-90	919	48	62 (8)
ALLO-IMT	Scotland	Hospital	Ischaemic stroke/TIA	2009-10	80	43	68 (10)
ASAP-NL	Netherlands	Hospital	Heterozygous FH	1997-98	325	61	49 (11)
ATIC	Netherlands	Hospital	Chronic renal failure	2001-02	93	43	53 (12)
AUDITOR	Multinational	Hospital	Obesity+metabolic syndrome	2005-06	661	49	63 (6)
BAS	China	Community screening	cIMT↑	2010	125	63	57 (5)
BK REGISTRY II	Korea	Hospital	Coronary stent	2000-03	205	32	60 (10)
CAMERA	Scotland	Hospital/GP lists	CHD	2009-11	173	23	63 (8)
CAPTIVATE	Multinational	Hospital	Heterozygous FH	2004-05	719	NP	NP
CERDIA	Netherlands	Hospital	T2DM	1999-01	250	53	58 (11)
CONTRAST	Multinational	Hospital	On haemodialysis	2004-09	714	38	64 (14)

EGE STUDY	Turkey	Hospital	On haemodialysis	2005-06	644	46	59 (14)
ENHANCE	Multinational	Hospital	Heterozygous FH	2002-06	720	49	47 (9)
FACIT	Netherlands	Municipal/blood bank registries	General population	2000-01	819	28	60 (6)
GRACE	Multinational	Hospital	Dysglycaemia+CVD RFs/CVD	2003-05	1,189	36	63 (8)
Gresele	Multinational	Hospital	Peripheral arterial disease	2003-05	442	21	67 (9)
HART	Canada	Hospital/GP lists	CVD/DM+ ≥ 1 CVD RF	1999-00	925	24	69 (7)
KIMVASC	Scotland	GP lists	CVD/hypertension/DM	2011-12	80	45	77 (5)
LIFE-ICARUS	Multinational	Hospital	Hypertension+LVH	1996-97	83	27	67 (6)
Masia	Spain	Hospital	HIV+ ≥ 2 CVD RFs	2006-07	68	10	52 (11)
MAVET	Australia	Newspaper advert	Smokers	1994-95	408	54	64 (6)
MEDICLAS	Multinational	Hospital	HIV	2003-05	48	0	42 (10)
MG600	Brazil	Hospital	Hypertension	2010-11	35	100	55 (7)
Nakamura II	Japan	Hospital	Chronic renal failure	2001	50	40	53 (7)
OPAL	Multinational	Hospital/GP lists/other ^a	General population	1997-99	866	100	59 (7)
PERIOCARDIO	Australia	Health facilities	Aboriginal Australians	2010-12	273	42	41 (10)
PREVEND IT	Netherlands	Population register	Microalbuminuria	1998-99	864	35	51 (12)
RADIANCE I	Multinational	Hospital	Heterozygous FH	2003-04	904	51	46 (13)
RADIANCE II	Multinational	Hospital	Mixed dyslipidaemia	2003-06	752	36	57 (8)
REGRESS	Netherlands	Hospital	CHD+TC 155-310 mg/dL	1989-91	255	0	56 (8)
RIS	Sweden	Hospital	Hypertension+ ≥ 1 CVD RF	1987-89	164	0	66 (5)
Safarova	Russia	Hospital	CHD	2007-09	60	0	55 (6)
SECURE	Canada	Hospital	CVD/DM+ ≥ 1 CVD RF	1994-95	731	24	66 (7)
STARR	Multinational	Hospital/GP lists/other ^b	Dysglycaemia	2001-03	1,320	55	53 (11)
STOP-NIDDM	Germany	High-risk population screening	Dysglycaemia	1996-98	119	42	54 (7)
VITAL	Netherlands	Hospital	Indication for statin use	2002-04	199	41	49 (12)
WELCOME	UK	Hospital	NAFLD	2010-11	103	42	51 (11)
Total				1980-14	106,846	50	59 (10)

CAPD, continuous ambulatory peritoneal dialysis; CHD, coronary heart disease; cIMT, carotid intima-media thickness; CVD, cardiovascular disease; DM, diabetes mellitus; FH, familial hypercholesterolaemia; GP, general practitioner; HIV, human immunodeficiency virus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LDL-C, low-density lipoprotein cholesterol; LVH, left ventricular hypertrophy; NAFLD, non-alcoholic fatty liver disease; NP, not provided; RF, risk factor; SD, standard deviation; TC, total cholesterol; TIA, transient ischaemic attack; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus. Full study names and references are provided in **Table S1**. ^aExisting ongoing population-based cohorts and advertisements in local print and broadcast media. ^bPublic advertising and news reports in the media, internet items, referral from relatives, poster displays, diabetes screening fairs and direct mailing campaigns.